Aytu BioPharma Inc [AYTU] stock prices are up 3.05% to $1.35 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AYTU shares have gain 11.57% over the last week, with a monthly amount glided 35.00%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Aytu BioPharma Inc [NASDAQ: AYTU] stock has seen the most recent analyst activity on March 30, 2021, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $11. Previously, H.C. Wainwright started tracking the stock with Buy rating on May 29, 2020, and set its price target to $3.
The stock price of Aytu BioPharma Inc [AYTU] has been fluctuating between $0.95 and $3.45 over the past year. Aytu BioPharma Inc [NASDAQ: AYTU] shares were valued at $1.35 at the most recent close of the market.
Analyzing the AYTU fundamentals
The Aytu BioPharma Inc [NASDAQ:AYTU] reported sales of 68.76M for trailing twelve months, representing a drop of -29.27%. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at -0.13%, Pretax Profit Margin comes in at -0.07%, and Net Profit Margin reading is -0.08%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.18 and Total Capital is -0.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.52.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3133 points at the first support level, and at 1.2767 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3933, and for the 2nd resistance point, it is at 1.4367.
Ratios To Look Out For
It’s worth pointing out that Aytu BioPharma Inc [NASDAQ:AYTU]’s Current Ratio is 0.98. Also, the Quick Ratio is 0.81, while the Cash Ratio stands at 0.32. Considering the valuation of this stock, the price to sales ratio is 0.12, the price to book ratio is 0.27.
Transactions by insiders
Recent insider trading involved Disbrow Joshua R., Chief Executive Officer, that happened on Feb 28 ’25 when 15000.0 shares were purchased.
